Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic-ecollection
Typ dokumentu tisková chyba
PubMed
38327519
PubMed Central
PMC10848160
DOI
10.3389/fimmu.2024.1369747
Knihovny.cz E-zdroje
- Klíčová slova
- PD-1/PD-L1 immune checkpoint inhibitors, autoimmune disease (AID), autoimmune hepatitis (AIH), autoimmune liver diseases (AILD), immune checkpoint inhibitors (ICI), immune related adverse effects (irAEs), primary biliary cholangitis (PBC), primary sclerosing cholangites (PSC),
- Publikační typ
- tisková chyba MeSH
[This corrects the article DOI: 10.3389/fimmu.2023.1326078.].
1 Department of Medicine University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Hepatogastroenterology Institute for Clinical and Experimental Medicine Prague Czechia
Department of Hepatology and Gastroenterology Charité Universitätsmedizin Berlin Berlin Germany
Department of Internal Medicine 1 University Hospital Regensburg Regensburg Germany
Department of Medicine 2 University Hospital Ludwig Maximilians Universität München Munich Germany
Epatocentro Ticino Lugano Switzerland
European Reference Network on Hepatological Diseases Hamburg Germany
Faculty of Biomedical Sciences Università della Svizzera Italiana Lugano Switzerland
Liver Unit Hospital Clinic Barcelona FCRB IDIBAPS CIBEREHD University of Barcelona Barcelona Spain
Service Hépato Gastro Entérologie Hôpital St Eloi CHU Montpellier Montpellier France
Citace poskytuje Crossref.org
